Literature DB >> 8551620

The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: a Vpu-like factor?

S Bour1, U Schubert, K Peden, K Strebel.   

Abstract

The Vpu protein is a human immunodeficiency virus type 1 (HIV-1)-specific accessory protein that is required for the efficient release of viral particles from infected cells. Even though HIV-2 does not encode Vpu, we found that this virus is nevertheless capable of efficiently releasing virus particles. In fact, the rate of virus release from HeLa cells transfected with a full-length molecular clone of HIV-2, ROD10, was comparable to that observed for the vpu+ HIV-1 NL4-3 isolate and was not further enhanced by expression of Vpu in trans. However, consistent with previous observations showing that HIV-2 particle release is Vpu responsive in the context of HIV-1/HIV-2 chimeric constructs; exchanging the gag-pol region of NL4-3 with the corresponding region from pROD10 rendered the resulting chimeric virus Vpu responsive. Our finding that the responsiveness of HIV-2 particle release to Vpu is context dependent suggested the presence of a Vpu-like factor(s) encoded by HIV-2. Using chimeric proviruses encoding HIV-2 gag and pol in the context of the HIV-1 provirus that were coexpressed with subgenomic HIV-2 constructs, we found that the HIV-2 envelope glycoprotein had the ability to enhance HIV-2 particle release with an efficiency comparable to that of the HIV-1 Vpu protein. Conversely, inactivation of the HIV-2 env gene in the original ROD10 clone resulted in a decrease in the rate of viral particle release to a level that was comparable to that of Vpu-deficient HIV-1 isolates. Providing the wild-type envelope in trans rescued the particle release defect of the ROD10 envelope mutant. Thus, unlike HIV-1, which encodes two separate proteins to regulate virus release or to mediate viral entry, the HIV-2 Env protein has evolved to perform both functions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8551620      PMCID: PMC189884     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  Sequences present in the cytoplasmic domain of CD4 are necessary and sufficient to confer sensitivity to the human immunodeficiency virus type 1 Vpu protein.

Authors:  R L Willey; A Buckler-White; K Strebel
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 Vpu protein is an oligomeric type I integral membrane protein.

Authors:  F Maldarelli; M Y Chen; R L Willey; K Strebel
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

3.  HIV-2 viral protein X association with the GAG p27 capsid protein.

Authors:  R Horton; P Spearman; L Ratner
Journal:  Virology       Date:  1994-03       Impact factor: 3.616

4.  The human immunodeficiency virus type 1 encoded Vpu protein is phosphorylated by casein kinase-2 (CK-2) at positions Ser52 and Ser56 within a predicted alpha-helix-turn-alpha-helix-motif.

Authors:  U Schubert; P Henklein; B Boldyreff; E Wingender; K Strebel; T Porstmann
Journal:  J Mol Biol       Date:  1994-02-11       Impact factor: 5.469

5.  Vpu-induced degradation of CD4: requirement for specific amino acid residues in the cytoplasmic domain of CD4.

Authors:  M E Lenburg; N R Landau
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 Vpu protein induces degradation of chimeric envelope glycoproteins bearing the cytoplasmic and anchor domains of CD4: role of the cytoplasmic domain in Vpu-induced degradation in the endoplasmic reticulum.

Authors:  M J Vincent; N U Raja; M A Jabbar
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

7.  Functional analysis of the phosphorylation sites on the human immunodeficiency virus type 1 Vpu protein.

Authors:  J Friborg; A Ladha; H Göttlinger; W A Haseltine; E A Cohen
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-01-01

8.  Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity.

Authors:  D F Purcell; M A Martin
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

Review 9.  Population migration and the spread of types 1 and 2 human immunodeficiency viruses.

Authors:  T C Quinn
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

10.  Differential activities of the human immunodeficiency virus type 1-encoded Vpu protein are regulated by phosphorylation and occur in different cellular compartments.

Authors:  U Schubert; K Strebel
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

View more
  58 in total

Review 1.  Human immunodeficiency virus and AIDS: insights from animal lentiviruses.

Authors:  R J Miller; J S Cairns; S Bridges; N Sarver
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

Review 2.  HIV-1 Vpu - an ion channel in search of a job.

Authors:  Klaus Strebel
Journal:  Biochim Biophys Acta       Date:  2013-07-03

Review 3.  Viroporins customize host cells for efficient viral propagation.

Authors:  Kristina M Giorda; Daniel N Hebert
Journal:  DNA Cell Biol       Date:  2013-08-14       Impact factor: 3.311

Review 4.  Novel approaches to inhibiting HIV-1 replication.

Authors:  Catherine S Adamson; Eric O Freed
Journal:  Antiviral Res       Date:  2009-09-24       Impact factor: 5.970

Review 5.  Foamy viruses are unconventional retroviruses.

Authors:  M L Linial
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

6.  Conformational changes induced by a single amino acid substitution in the trans-membrane domain of Vpu: implications for HIV-1 susceptibility to channel blocking drugs.

Authors:  Sang Ho Park; Stanley J Opella
Journal:  Protein Sci       Date:  2007-08-31       Impact factor: 6.725

7.  Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein.

Authors:  Rachel L Kaletsky; Joseph R Francica; Caroline Agrawal-Gamse; Paul Bates
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-28       Impact factor: 11.205

8.  Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.

Authors:  Janet L Douglas; Kasinath Viswanathan; Matthew N McCarroll; Jean K Gustin; Klaus Früh; Ashlee V Moses
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

9.  Human immunodeficiency virus type 2 glycoprotein enhancement of particle budding: role of the cytoplasmic domain.

Authors:  G D Ritter; G Yamshchikov; S J Cohen; M J Mulligan
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

10.  Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production.

Authors:  Vasundhara Varthakavi; Rita M Smith; Stephan P Bour; Klaus Strebel; Paul Spearman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.